Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Bristol Myers was down 3.8% to $50.75 after the company said a clinical study using a combination of the drugs Opdivo and Yervoy didn't significantly improve survival rates in patients with extensive-stage small cell lung cancer vs. placebo.